DALLAS , Aug. 18, 2025 /PRNewswire/ -- Braemar Hotels & Resorts Inc. (NYSE: BHR) ("Braemar" or the "Company") announced today that it has successfully refinanced the existing mortgage loan secured by the Four Seasons Resort Scottsdale at Troon North. The previous loan had a balance of $140 million with an interest rate of SOFR + 3.75% and a final maturity in December 2028.

RICHARDSON, Texas, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Optex Systems Holdings, Inc. (Nasdaq: OPXS), a leading manufacturer of precision optical sighting systems for domestic and worldwide military and commercial applications, is confirmed to present at the 2025 Annual Gateway Conference, which is being held September 3-4 at the Four Seasons Hotel in San Francisco, CA.

~ Strengthens Leadership Incentives and Alignment Around Long-Term Growth Objectives and Disciplined Capital Allocation ~

Kingsway Search Xcelerator's 12th Acquisition Asset-light plumbing services business with recurring revenues and leading market position Purchase price of $5.625 million, plus a potential earn-out of up to $1.125 million, for a total maximum purchase price of $6.75 million Unaudited pro-forma annual revenue of $4.0 million Unaudited pro-forma annual adjusted EBITDA of $0.9 million New credit facility to support growth at Kingsway Skilled Trades CHICAGO, ILLINOIS / ACCESS Newswire / August 18, 2025 / (NYSE:KFS) Kingsway Financial Services Inc. ("Kingsway" or the "Company"), the only publicly-traded US company employing the Search Fund model to acquire and build great businesses, today …

BDX is now attractively valued with a forward PE of 13.7, well below its historical average, making it a compelling value stock. Strong growth in Pharmaceutical Systems and Interventional segments, margin expansion, and a robust innovation pipeline drive business momentum. The upcoming Waters Corp. spin-out will focus BDX on high-growth, recurring revenue segments, enhancing long-term earnings potential.

– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related IRD.

CHARLOTTE, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (NASDAQ: AMOD) (“Alpha Modus” or the “Company”), a leader in AI-powered retail engagement technologies, today announced that it has entered into an agreement for a transformative capital restructuring that will eliminate approximately $41 million in mezzanine equity, dramatically reduce the Company's stockholders' deficit, retire its last remaining preferred stock, and deliver a cleaner, shareholder-aligned capital structure designed for sustainable growth.

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) between November 7 , 202 4 and Ju ly 8 , 202 5, inclusive. Should You Join This Class Action Lawsuit?

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired publicly traded Sable Offshore Corp. (“Sable Offshore” or the “Company”) (NYSE: SOC) securities between May 19, 2025 and June 3, 2025, inclusive (the “Class Period”), and/or pursuant and/or traceable to the Company's May 21, 2025 secondary public offering. Should You Join This Class Action Lawsuit?

-- Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia -- -- NewAmsterdam entitled to tiered double-digit percentage royalties ranging from the low double-digits to mid-twenties on net sales in the Menarini Territory and up to an additional €833 million upon the achievement of various clinical, regulatory and commercial milestones --

Company expects to complete BLA submission in the fourth quarter of 2025 Company expects to complete BLA submission in the fourth quarter of 2025

-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- - Reports on New Findings Published in Scientific Journal Nature that Validate LIXTE's Ongoing Clinical Trials with LB-100- -Launches New Pre-Clinical Study- PASADENA, Calif, Aug. 18, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on its recent activities. “This has been a transformative period for our company,” …

BOCA RATON, FL, Aug. 18, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that it will participate in a webcast presentation at the Lytham Partners 2025 Consumer & Technology Investor Summit, taking place virtually on Tuesday, August 19, 2025.

AUSTIN, Texas, Aug. 18, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The GotStocks Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025.

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of SelectQuote, Inc. (“SelectQuote” or the “Company”) (NYSE: SLQT) between September 9 , 202 0 and May 1 , 202 5, inclusive. Should You Join This Class Action Lawsuit?

EDISON, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS) manufactured in the United States, today announced the appointment of long-time operations leader, John Mahaz, as Chief Operating Officer (COO).

DALLAS, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD) announced today it plans to break ground in September 2025 on Polaris Forge 2, a $3 billion, 280-megawatt (MW) AI Factory near Harwood, North Dakota. Designed with the ability to scale beyond its initial 280MW, the campus—with initial capacity in 2026 and reaching full capacity in early 2027—further advances Applied Digital's rapid growth and reinforces North Dakota's position as one of the most strategically important destinations for AI infrastructure in the United States.

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus" or the "Company") (Nasdaq: LOT), a leading global intelligent and luxury mobility provider, today announced that it will report its unaudited financial results for the first half 2025 on August 29, 2025, before market opening in the United States. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on Friday, August 29, 2025 (14:00 Central European Time / 20:00 China Standard Time on the same day).

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired: (a) Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about February 2, 2024 (the “IPO” or “Offering”); and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive. Should You Join This Class Action Lawsuit?